Kaveri Pohlman
Stock Analyst at Clear Street
(4.23)
# 1,420
Out of 4,456 analysts
231
Total ratings
40.4%
Success rate
10.8%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kaveri Pohlman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MLTX MoonLake Immunotherapeutics | Maintained: Buy | $70 | $19.90 | +251.76% | 6 | Jun 22, 2026 | |
| CGEM Cullinan Therapeutics | Maintained: Buy | $33 → $46 | $18.40 | +150.00% | 19 | Jun 10, 2026 | |
| LBRX LB Pharmaceuticals | Initiated Coverage: Buy | $45 | $31.92 | +40.98% | 1 | May 26, 2026 | |
| SGMT Sagimet Biosciences | Maintained: Buy | $37 → $28 | $7.06 | +296.60% | 4 | May 13, 2026 | |
| TRVI Trevi Therapeutics | Maintained: Buy | $21 → $29 | $18.15 | +59.78% | 3 | May 7, 2026 | |
| MDGL Madrigal Pharmaceuticals | Maintained: Buy | $533 → $680 | $512.65 | +32.64% | 3 | May 6, 2026 | |
| ORKA Oruka Therapeutics | Maintained: Buy | $71 → $131 | $90.60 | +44.59% | 4 | Apr 27, 2026 | |
| ELVN Enliven Therapeutics | Maintained: Buy | $36 → $55 | $50.08 | +9.82% | 2 | Apr 27, 2026 | |
| PTGX Protagonist Therapeutics | Maintained: Buy | $104 → $116 | $121.88 | -4.82% | 5 | Apr 6, 2026 | |
| PALI Palisade Bio | Maintained: Buy | $12 | $1.89 | +534.92% | 2 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $53 | $25.18 | +110.48% | 1 | Mar 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $11 → $20 | $16.01 | +24.92% | 3 | Mar 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $200 → $220 | $148.21 | +48.44% | 3 | Mar 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $32 → $12 | $14.94 | -19.68% | 4 | Jan 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $9.53 | +88.88% | 1 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $61 → $99 | $49.71 | +99.16% | 2 | Dec 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $25 | $22.00 | +13.64% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $18 | $5.35 | +236.45% | 2 | Dec 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $5.65 | +112.39% | 17 | Nov 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $32 → $47 | $34.00 | +38.24% | 2 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $54.77 | n/a | 8 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $4.81 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $15.05 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $31.00 | n/a | 30 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $26.12 | n/a | 18 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.63 | n/a | 13 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $6.44 | n/a | 16 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $2.77 | n/a | 4 | Nov 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $13 | $3.68 | n/a | 17 | Jun 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $21 | $1.42 | n/a | 1 | Apr 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $0.000001 | n/a | 6 | Nov 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $16 → $8 | $3.40 | n/a | 3 | Jul 6, 2022 |
MoonLake Immunotherapeutics
Jun 22, 2026
Maintained: Buy
Price Target: $70
Current: $19.90
Upside: +251.76%
Cullinan Therapeutics
Jun 10, 2026
Maintained: Buy
Price Target: $33 → $46
Current: $18.40
Upside: +150.00%
LB Pharmaceuticals
May 26, 2026
Initiated Coverage: Buy
Price Target: $45
Current: $31.92
Upside: +40.98%
Sagimet Biosciences
May 13, 2026
Maintained: Buy
Price Target: $37 → $28
Current: $7.06
Upside: +296.60%
Trevi Therapeutics
May 7, 2026
Maintained: Buy
Price Target: $21 → $29
Current: $18.15
Upside: +59.78%
Madrigal Pharmaceuticals
May 6, 2026
Maintained: Buy
Price Target: $533 → $680
Current: $512.65
Upside: +32.64%
Oruka Therapeutics
Apr 27, 2026
Maintained: Buy
Price Target: $71 → $131
Current: $90.60
Upside: +44.59%
Enliven Therapeutics
Apr 27, 2026
Maintained: Buy
Price Target: $36 → $55
Current: $50.08
Upside: +9.82%
Protagonist Therapeutics
Apr 6, 2026
Maintained: Buy
Price Target: $104 → $116
Current: $121.88
Upside: -4.82%
Palisade Bio
Mar 31, 2026
Maintained: Buy
Price Target: $12
Current: $1.89
Upside: +534.92%
Mar 17, 2026
Initiated Coverage: Buy
Price Target: $53
Current: $25.18
Upside: +110.48%
Mar 6, 2026
Rated: Buy
Price Target: $11 → $20
Current: $16.01
Upside: +24.92%
Mar 2, 2026
Maintained: Buy
Price Target: $200 → $220
Current: $148.21
Upside: +48.44%
Jan 20, 2026
Downgraded: Hold
Price Target: $32 → $12
Current: $14.94
Upside: -19.68%
Dec 11, 2025
Reiterated: Buy
Price Target: $18
Current: $9.53
Upside: +88.88%
Dec 9, 2025
Maintained: Buy
Price Target: $61 → $99
Current: $49.71
Upside: +99.16%
Dec 1, 2025
Maintained: Buy
Price Target: $25
Current: $22.00
Upside: +13.64%
Dec 1, 2025
Maintained: Buy
Price Target: $18
Current: $5.35
Upside: +236.45%
Nov 26, 2025
Maintained: Buy
Price Target: $12
Current: $5.65
Upside: +112.39%
Nov 11, 2025
Maintained: Buy
Price Target: $32 → $47
Current: $34.00
Upside: +38.24%
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $54.77
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $4.81
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $15.05
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $31.00
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $26.12
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $11.63
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $6.44
Upside: n/a
Nov 29, 2024
Rated: Hold
Price Target: n/a
Current: $2.77
Upside: n/a
Jun 2, 2024
Maintained: Buy
Price Target: $13
Current: $3.68
Upside: n/a
Apr 29, 2024
Maintained: Buy
Price Target: $21
Current: $1.42
Upside: n/a
Nov 23, 2022
Downgraded: Hold
Price Target: n/a
Current: $0.000001
Upside: n/a
Jul 6, 2022
Rated: Buy
Price Target: $16 → $8
Current: $3.40
Upside: n/a